- Home
- EDRY vs NNVC Comparison
EDRY vs NNVC Comparison
Compare EDRY & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- NNVC
- Stock Information
- Founded
- EDRY 2018
- NNVC 2005
- Country
- EDRY Greece
- NNVC United States
- Employees
- EDRY N/A
- NNVC N/A
- Industry
- EDRY Marine Transportation
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- NNVC Health Care
- Exchange
- EDRY Nasdaq
- NNVC Nasdaq
- Market Cap
- EDRY 27.3M
- NNVC 22.5M
- IPO Year
- EDRY N/A
- NNVC N/A
- Fundamental
- Price
- EDRY $10.89
- NNVC $1.49
- Analyst Decision
- EDRY
- NNVC
- Analyst Count
- EDRY 0
- NNVC 0
- Target Price
- EDRY N/A
- NNVC N/A
- AVG Volume (30 Days)
- EDRY 1.4K
- NNVC 130.0K
- Earning Date
- EDRY 08-11-2025
- NNVC 09-26-2025
- Dividend Yield
- EDRY N/A
- NNVC N/A
- EPS Growth
- EDRY N/A
- NNVC N/A
- EPS
- EDRY N/A
- NNVC N/A
- Revenue
- EDRY $49,707,775.00
- NNVC N/A
- Revenue This Year
- EDRY N/A
- NNVC N/A
- Revenue Next Year
- EDRY $28.45
- NNVC N/A
- P/E Ratio
- EDRY N/A
- NNVC N/A
- Revenue Growth
- EDRY N/A
- NNVC N/A
- 52 Week Low
- EDRY $7.60
- NNVC $0.94
- 52 Week High
- EDRY $20.80
- NNVC $1.92
- Technical
- Relative Strength Index (RSI)
- EDRY 54.94
- NNVC 51.75
- Support Level
- EDRY $10.88
- NNVC $1.40
- Resistance Level
- EDRY $11.00
- NNVC $1.54
- Average True Range (ATR)
- EDRY 0.13
- NNVC 0.07
- MACD
- EDRY 0.01
- NNVC 0.00
- Stochastic Oscillator
- EDRY 70.60
- NNVC 65.22
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.